Welcome to our dedicated page for Apria news (Ticker: APR), a resource for investors and traders seeking the latest updates and insights on Apria stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Apria's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Apria's position in the market.
Apria, Inc. (Nasdaq: APR) has appointed Michael-Bryant Hicks as its new Executive Vice President, General Counsel, and Corporate Secretary. Hicks, previously with Elanco Animal Health and with extensive legal experience in healthcare, replaces Raoul Smyth, who retired after 25 years at Apria, including directing the company's legal functions during its recent IPO. Hicks's appointment is seen as an effort to strengthen legal leadership as Apria continues to grow.
Apria, Inc. announced the pricing of its initial public offering (IPO) of 7,500,000 shares at $20.00 each, scheduled to trade on Nasdaq under the symbol 'APR' starting February 11, 2021. The underwriters have a 30-day option for an additional 1,125,000 shares. The IPO closing is expected on February 16, 2021. Notably, Apria will not receive any proceeds from this offering as the shares are sold by existing stockholders. Major financial institutions, including Citigroup and Goldman Sachs, are managing the offering.
Apria announced an initial public offering (IPO) of 7,500,000 shares of common stock priced between $19.00 and $21.00 per share, with an option for underwriters to purchase an additional 1,125,000 shares. The company will not receive any net proceeds from the sale, as the shares are being sold by existing stockholders. Apria's shares will be listed on the Nasdaq under the symbol APR. Citigroup and Goldman Sachs are leading the offering, with several other firms acting as joint book-running managers.